Provexis plc has announced that it is entering into a development agreement with DSM Nutritional Products to develop a new ingredient based on DSM-owned intellectual property. Provexis will develop the naturally-derived casein, progress through clinical trials and gain the necessary regulatory approvals. The partners will together identify the most appropriate commercialisation arrangements before the product is launched.
This marks a second collaboration for the two companies, after Provexis’ proprietary heart health technology Fruitflow® was licensed to DSM in 2010. The acquisition serves to further strengthen Provexis’ pipeline of innovative technologies for the functional and medical foods sectors. This now includes a plantain-derived extract for the treatment of Crohn’s disease and work on an ingredient derived from cruciferous vegetables for cardiovascular inflammation. This latter research is being conducted in collaboration with the Institute of Food Research, Norwich, UK.
Stephen Moon, Chief Executive Officer at Provexis plc, comments: “We are delighted to be entering into a development agreement with DSM on this new ingredient. From our experience with the development and commercialisation of Fruitflow®, we know that there is a synergy between the two companies and that we can work together to create highly functional and profitable health and nutrition ingredients.”
“It is estimated that by 2025, over 4 million people in the UK will suffer from diabetes.” continues Stephen. “Consumer awareness of the condition and the associated cardiovascular risks is growing, and people are starting to look for effective and convenient ways to manage their blood glucose levels. This intellectual property will allow us to develop an ingredient backed by rigorous scientific investigation that will respond effectively to the growing demands of a flourishing market.”